Company Reports Q4 Revenue of $421M, CEO Highlights Significant Progress in 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Reports Q4 revenue $421M vs. $501M last year. Cash and short-term investments of $8.6M at the end of 2025 are believed to be sufficient to provide operating runway through approximately 2Q27. "2025 marked meaningful progress, with continued field validation, revenue growth, improved margins, and a stronger balance sheet," said CEO Joel Fruendt. "We believe field validation of efficacy becomes a powerful catalyst for expanded acceptance in the market, as reflected in the strong growth of our e-commerce channel, which is now more than 50% of our annual revenue. We are leaning further into the direct-to-consumer and e-commerce opportunities, strengthening our control of the customer experience, improving performance management, and enhancing our ability to capture more value as adoption expands." "With a CEO transition plan underway, the Board remains focused on continuity, alignment, and disciplined execution as we support management in scaling the business," said Jamie Bechtel, Interim Executive Chair. "With a growing body of validation and a sharpened go-to-market approach, we are focused on executing with discipline, expanding adoption, and building long-term stockholder value."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNES?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNES
Wall Street analysts forecast SNES stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.820
Low
10.00
Averages
10.00
High
10.00
Current: 1.820
Low
10.00
Averages
10.00
High
10.00
No data
About SNES
SenesTech, Inc. develops and commercializes products for managing animal pest populations, initially rat populations, through fertility control. The Company’s product lines of fertility control products are: ContraPest, Evolve Rat, and Evolve Mouse. Its product, ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest targets the reproductive systems of both male and female Norway and roof rats beginning with the first breeding cycle following consumption, which can lead to sustained reductions in the rat population. The Evolve Rat is a soft bait product that contains the active ingredient, cottonseed oil, which reduces fertility in both male and female rats. The Evolve Mouse, a modified version of soft bait technology containing the active ingredient cottonseed oil, which limits reproduction of male and female mice after one to two breeding cycles following consumption.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SenesTech to Participate in 2026 Investor Conference
- Webcast Schedule: SenesTech will host a webcast on May 28, 2026, at 2:30 p.m. ET, accessible via the conference homepage, enhancing investor engagement and transparency.
- One-on-One Meeting Opportunities: Management will participate in virtual one-on-one meetings during the event, allowing investors to arrange discussions with the company, aimed at strengthening relationships and driving funding opportunities.
- Commitment to Product Innovation: SenesTech focuses on managing animal pest populations through fertility control, with its Evolve product effectively integrated into pest management programs, reducing reliance on traditional poisons and reflecting the company's strategic commitment to sustainability.
- Forward-Looking Statement Caution: The press release includes forward-looking statements regarding market acceptance, financial performance, and product commercialization risks, advising investors to consider potential uncertainties for informed investment decisions.
See More
SenesTech to Participate in 2026 Investor Conference
- Investor Conference Participation: SenesTech will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026, with a webcast presentation scheduled for 2:30 PM ET, aimed at enhancing the company's visibility among investors and attracting potential investment.
- One-on-One Meeting Opportunities: Management will engage in virtual one-on-one meetings throughout the event, allowing investors to arrange discussions with the team, which helps strengthen investor relations and delve into the company's strategies and future plans.
- Commitment to Product Innovation: SenesTech focuses on managing animal pest populations through fertility control, with products like Evolve rodent birth control designed to reduce reliance on traditional poisons, thereby enhancing pest management effectiveness and promoting sustainability and environmental health.
- Forward-Looking Statement Risks: The press release includes forward-looking statements regarding market acceptance, financial performance, and product commercialization, indicating that the company faces uncertainties in achieving growth objectives, which investors should carefully consider when assessing potential risks.
See More
SenesTech Q1 2026 Earnings Call Insights
- Direct-to-Consumer Growth: SenesTech reported a 42% increase in direct-to-consumer revenue for Q1, reaching a record $194,000, indicating strong performance in this core growth engine and expected to further drive overall revenue growth.
- E-commerce Sales Surge: Following the direct management of its Amazon account, April e-commerce sales soared 163% to $146,000, demonstrating early success in the company's e-commerce transformation and potential for continued market share expansion.
- Strong Financial Performance: Total revenue for Q1 was $493,000, despite approximately $443,000 in one-time expenses, with gross margin improving to 68.6%, reflecting enhanced cost control and profitability, which strengthens future financial flexibility.
- Strategic Execution Priority: Management emphasized that “commercial execution at scale” is the current central priority, with plans to expand the Evolve brand and launch new products, showcasing the company's proactive positioning in the competitive landscape and confidence in future growth.
See More
SenesTech Reports Strong E-Commerce Transition Results in Q1 2026
- E-Commerce Transition Success: Under the leadership of new CEO Michael Edell, SenesTech's direct-to-consumer revenue surged 42% to a record $194,000 in Q1, reflecting strong market demand and growth potential as the company transitions to in-house Amazon management.
- Record Gross Margin: The gross margin reached a historic high of 68.6% in Q1, indicating significant progress in operational optimization and cost control, thereby laying a solid foundation for sustainable future growth.
- Accelerating Subscription Sales: With direct control over e-commerce channels, subscription sales have continued to accelerate, breaking previous revenue records and demonstrating increasing consumer acceptance of non-toxic rodent management solutions, enhancing the company's competitive position.
- Strategic Investment Focus: Edell emphasized that by improving customer experience and conversion rates, SenesTech is building a more predictable recurring revenue model aimed at achieving sustainable business growth in the long term, aligning with the company's strategic vision for future markets.
See More
SenesTech to Release Q1 2026 Financial Results
- Earnings Release Schedule: SenesTech is set to announce its Q1 2026 financial results after market close on May 12, 2026, reflecting the company's ongoing commitment to managing animal pest populations.
- Conference Call Timing: A conference call will be held on the same day at 5:00 PM ET to review the financial results, aimed at enhancing investor understanding and confidence in the company's performance.
- Live Webcast Information: Interested parties can access the conference call via a live webcast available in the Investor Relations section of the company's website, ensuring transparency and fostering investor engagement.
- Product Mission: SenesTech is dedicated to improving environments through humane birth control products, highlighting its innovation in reducing reliance on traditional poisons and showcasing the company's strategic positioning in sustainability.
See More
SenesTech to Release Q1 2026 Financial Results and Host Conference Call
- Financial Report Schedule: SenesTech will release its Q1 2026 financial results after market close on May 12, 2026, reflecting the company's ongoing commitment to transparency in animal pest management.
- Conference Call Timing: On the same day, SenesTech will hold a conference call at 5:00 PM ET to discuss the financial results in detail and engage with investors, thereby enhancing investor confidence.
- Live Webcast Information: Interested parties can access the conference call via a live webcast available on the company's Investor Relations page, ensuring broad participation and information dissemination to boost corporate transparency.
- Company Mission and Vision: SenesTech is dedicated to improving environments through humane birth control products, reducing reliance on traditional poisons, and promoting sustainability, showcasing its leadership position in the industry.
See More
SenesTech to Participate in 2026 Investor Conference
- Webcast Schedule: SenesTech will host a webcast on May 28, 2026, at 2:30 p.m. ET, accessible via the conference homepage, enhancing investor engagement and transparency.
- One-on-One Meeting Opportunities: Management will participate in virtual one-on-one meetings during the event, allowing investors to arrange discussions with the company, aimed at strengthening relationships and driving funding opportunities.
- Commitment to Product Innovation: SenesTech focuses on managing animal pest populations through fertility control, with its Evolve product effectively integrated into pest management programs, reducing reliance on traditional poisons and reflecting the company's strategic commitment to sustainability.
- Forward-Looking Statement Caution: The press release includes forward-looking statements regarding market acceptance, financial performance, and product commercialization risks, advising investors to consider potential uncertainties for informed investment decisions.
See More
SenesTech to Participate in 2026 Investor Conference
- Investor Conference Participation: SenesTech will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026, with a webcast presentation scheduled for 2:30 PM ET, aimed at enhancing the company's visibility among investors and attracting potential investment.
- One-on-One Meeting Opportunities: Management will engage in virtual one-on-one meetings throughout the event, allowing investors to arrange discussions with the team, which helps strengthen investor relations and delve into the company's strategies and future plans.
- Commitment to Product Innovation: SenesTech focuses on managing animal pest populations through fertility control, with products like Evolve rodent birth control designed to reduce reliance on traditional poisons, thereby enhancing pest management effectiveness and promoting sustainability and environmental health.
- Forward-Looking Statement Risks: The press release includes forward-looking statements regarding market acceptance, financial performance, and product commercialization, indicating that the company faces uncertainties in achieving growth objectives, which investors should carefully consider when assessing potential risks.
See More
SenesTech Q1 2026 Earnings Call Insights
- Direct-to-Consumer Growth: SenesTech reported a 42% increase in direct-to-consumer revenue for Q1, reaching a record $194,000, indicating strong performance in this core growth engine and expected to further drive overall revenue growth.
- E-commerce Sales Surge: Following the direct management of its Amazon account, April e-commerce sales soared 163% to $146,000, demonstrating early success in the company's e-commerce transformation and potential for continued market share expansion.
- Strong Financial Performance: Total revenue for Q1 was $493,000, despite approximately $443,000 in one-time expenses, with gross margin improving to 68.6%, reflecting enhanced cost control and profitability, which strengthens future financial flexibility.
- Strategic Execution Priority: Management emphasized that “commercial execution at scale” is the current central priority, with plans to expand the Evolve brand and launch new products, showcasing the company's proactive positioning in the competitive landscape and confidence in future growth.
See More
SenesTech Reports Strong E-Commerce Transition Results in Q1 2026
- E-Commerce Transition Success: Under the leadership of new CEO Michael Edell, SenesTech's direct-to-consumer revenue surged 42% to a record $194,000 in Q1, reflecting strong market demand and growth potential as the company transitions to in-house Amazon management.
- Record Gross Margin: The gross margin reached a historic high of 68.6% in Q1, indicating significant progress in operational optimization and cost control, thereby laying a solid foundation for sustainable future growth.
- Accelerating Subscription Sales: With direct control over e-commerce channels, subscription sales have continued to accelerate, breaking previous revenue records and demonstrating increasing consumer acceptance of non-toxic rodent management solutions, enhancing the company's competitive position.
- Strategic Investment Focus: Edell emphasized that by improving customer experience and conversion rates, SenesTech is building a more predictable recurring revenue model aimed at achieving sustainable business growth in the long term, aligning with the company's strategic vision for future markets.
See More
SenesTech to Release Q1 2026 Financial Results
- Earnings Release Schedule: SenesTech is set to announce its Q1 2026 financial results after market close on May 12, 2026, reflecting the company's ongoing commitment to managing animal pest populations.
- Conference Call Timing: A conference call will be held on the same day at 5:00 PM ET to review the financial results, aimed at enhancing investor understanding and confidence in the company's performance.
- Live Webcast Information: Interested parties can access the conference call via a live webcast available in the Investor Relations section of the company's website, ensuring transparency and fostering investor engagement.
- Product Mission: SenesTech is dedicated to improving environments through humane birth control products, highlighting its innovation in reducing reliance on traditional poisons and showcasing the company's strategic positioning in sustainability.
See More
SenesTech to Release Q1 2026 Financial Results and Host Conference Call
- Financial Report Schedule: SenesTech will release its Q1 2026 financial results after market close on May 12, 2026, reflecting the company's ongoing commitment to transparency in animal pest management.
- Conference Call Timing: On the same day, SenesTech will hold a conference call at 5:00 PM ET to discuss the financial results in detail and engage with investors, thereby enhancing investor confidence.
- Live Webcast Information: Interested parties can access the conference call via a live webcast available on the company's Investor Relations page, ensuring broad participation and information dissemination to boost corporate transparency.
- Company Mission and Vision: SenesTech is dedicated to improving environments through humane birth control products, reducing reliance on traditional poisons, and promoting sustainability, showcasing its leadership position in the industry.
See More
